Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407843 | 1.00 | — | — | |
| SCHEMBL14964613 | 1.00 | KDM4E (0.31) | KDM4ELMNA | |
| SCHEMBL10809685 | 1.00 | KDM4E (0.31) | KDM4ELMNA | |
| SCHEMBL27078 | 0.90 | — | — | |
| Potassium Ion SCHEMBL28671648 | 0.84 | — | — | |
| SCHEMBL8580513 | 0.83 | — | — | |
| SCHEMBL12154107 | 0.83 | — | — | |
| SCHEMBL1807609 | 0.77 | — | — | |
| SCHEMBL1602883 | 0.77 | RECQL (0.34) | KDM4E | |
| SCHEMBL31103598 | 0.77 | RECQL (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006472-B2 | Methods for the synthesis of 13C labeled plasmalogen | PHENOMENOME DISCOVERIES INC. (CA) | 2015-04-14 | — | — | US | disclosed |
| US-9006472-B2 | Methods for the synthesis of 13C labeled plasmalogen | PHENOMENOME DISCOVERIES INC. (CA) | 2015-04-14 | — | — | US | disclosed |
| US-9006472-B2 | Methods for the synthesis of 13C labeled plasmalogen | PHENOMENOME DISCOVERIES INC. (CA) | 2015-04-14 | — | — | US | disclosed |
| US-20140336397-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD | MED-LIFE DISCOVERIES LP (CA) | 2014-11-13 | — | — | US | disclosed |
| US-20140336397-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD | MED-LIFE DISCOVERIES LP (CA) | 2014-11-13 | — | — | US | disclosed |
| US-20140336397-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD | MED-LIFE DISCOVERIES LP (CA) | 2014-11-13 | — | — | US | disclosed |
| US-20140323749-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | MED-LIFE DISCOVERIES LP (CA) | 2014-10-30 | — | — | US | disclosed |
| US-20140323749-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | MED-LIFE DISCOVERIES LP (CA) | 2014-10-30 | — | — | US | disclosed |
| US-20140323749-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | MED-LIFE DISCOVERIES LP (CA) | 2014-10-30 | — | — | US | disclosed |
| WO-2013071412-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | PHENOMENOME DISCOVERIES INC. (CA) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071411-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD | PHENOMENOME DISCOVERIES INC. (CA) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071411-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD | PHENOMENOME DISCOVERIES INC. (CA) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323749-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | PLPBP, SGMS2, PCCA | KDM4E 4058/4885LMNA 290/4885 |
| US-20140336397-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD | FASN, ALOX5, ALOX15 | KDM4E 2160/4885LMNA 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.